Ofichem Header Ofichem Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of CPDC Centre for Probe Development and Commercialization.

    Client Virtual Booth

    CPDC CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CPDC Centre for Probe Development and Commercialization
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    McMaster University Nuclear Research Building 1280 Main Street West Hamilton, Ontario,L8S 4K1
    Telephone
    Telephone
    (905) 525-9140
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imagingprobes.ca/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

    Details:

    177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.


    Lead Product(s): No-Carrier-Added Lutetium-177

    Therapeutic Area: Oncology Product Name: n.c.a 177 Lu

    Highest Development Status: N/AProduct Type: Small molecule

    Recipient: Isotopia

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 09, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The Centre for Probe Development and Commercialization Expands Into Asia and Executes a Development, Manufacturing, and Clinical Supply Agreement For 17...

    Details:

    Under the terms of the agreement, CPDC will develop and manufacture CellBion's drug product Lu-177-PSMA-D GUL, for Phase II clinical supply in South Korea with the goal of expanding into North America.


    Lead Product(s): Lu-177-PSMA-D GUL

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: CellBion

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 25, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    lgm-pharma-m-2024-07-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search